Table 1.

Patient characteristics and correlation with CTC detection before and/or after neoadjuvant chemotherapy

PreCT (n = 97 patients)
PostCT (n = 86 patients)
PreCT and/or postCT (n = 118 patients)
n (%)CTC positive (n = 22)P2)n (%)CTC positive (n = 15)P2)n (%)CTC positive (n = 32)P2)
Age
    ≤5062 (64%)1856 (65%)1276 (64%)27 (36%)
    >5035 (36%)40.0830 (35%)30.3042 (36%)5 (12%)0.005
Tumor size
    T1 and T253 (55%)1247 (55%)765 (55%)16 (25%)
    T3 and T444 (45%)100.9939 (45%)80.4953 (45%)16 (30%)0.54
Node
    N037 (38%)829 (38%)543 (36%)11 (26%)
    N1 and N260 (72%)140.8457 (72%)100.9775 (64%)21 (28%)0.83
Histology
    Ductal87 (88%)1977 (88%)13104 (88%)28 (27%)
    Lobular6 (7%)18 (7%)29 (8%)2 (22%)
    Other4 (5%)20.451 (5%)00.765 (4%)2 (40%)0.77
Tumor grade
    1 and 251 (53%)1245 (52%)761 (52%)16 (26%)
    346 (47%)100.8341 (48%)80.6357 (48%)16 (28%)0.83
Hormone receptors
    ER or PgR positive58 (60%)1254 (60%)971 (60%)16 (22%)
    ER and PgR negative39 (40%)100.1232 (40%)60.8047 (40%)16 (34%)0.20
HER2
    Positive24 (25%)726 (30%)535 (30%)11 (31%)
    Negative73 (75%)150.3969 (70%)100.7783 (70%)21 (25%)0.50
Pathologic response
    pCR19 (20%)417 (20%)223 (19%)6 (23%)
    Non-pCR78 (80%)180.8469 (80%)130.4795 (81%)26 (27%)0.90
  • Abbreviations: CTC, circulating tumor cells; pCR, pathologic complete response; preCT, preneoadjuvant chemotherapy; postCT, postneoadjuvant chemotherapy; ER, estrogen receptor; PgR, progesterone receptor.